Buparlisib (BKM120, NVP-BKM120)

目录号：S2247

Buparlisib (BKM120, NVP-BKM120) Chemical Structure

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂，在无细胞试验中作用于p110α/β/δ/γ的IC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34，mTOR，DNAPK 的作用效果下降，而对 PI4Kβ几乎没有活性。Phase 2。

规格 价格 库存 购买数量  
In DMSO RMB 2227.95 现货
RMB 1400.12 现货
RMB 2607.65 现货
RMB 7928.28 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck该产品发表文献78篇：

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂，在无细胞试验中作用于p110α/β/δ/γ的IC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34，mTOR，DNAPK 的作用效果下降，而对 PI4Kβ几乎没有活性。Phase 2。
特性 BKM120是可用于口服的生物有效的PI3K抑制剂。
靶点
p110α [1]
(Cell-free assay)		 p110δ [1]
(Cell-free assay)		 p110β [1]
(Cell-free assay)		 p110γ [1]
(Cell-free assay)		 Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
体外研究

BKM120作用于解除PI3K调节的细胞系，包括A2780, U87MG, MCF7和DU145时，具有抗增殖活性，GI50为0.1-0.7 nM。[1] BKM120诱导多发性骨髓瘤细胞(ARP1, ARK, MM.1S, MM1.R和U266)凋亡，导致G1期细胞增多，S期细胞减少。BKM120诱导CD138+原代MM 细胞凋亡，且作用于CD138−基质细胞时毒性较低。BKM120可引起BimS的上调和XIAP的下调。[2]BKM120作用于人类胃癌细胞系，降低mTOR下游信号，具有抗增殖活性。BKM120作用于KRAS突变的胃癌细胞系，可以增强p-ERK或 p-STAT3。BKM120 和STAT3阻断剂联用, 作用于含突变KRAS的细胞，诱导凋亡，具有协同效应，但是作用于KRAS野生型细胞没有这种效果。[3]BKM120主要通过Aurora B激酶调节有丝分裂崩坏。[4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MkHiR5l1d3SxeHnjJGF{e2G7 NFPkfZY4OiCq NF[yVGFFVVOR NW\qeppUS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCneIDy[ZN{cW6pIGDJN2tidHCqYTDFOVQ2UyCvdYThcpQhf2m2aDDHTVUxKG:oIECuNFAxOTV6IN88US=> NF\lVoYzPDlyMEK2Oi=>
DU145 M3u3bGN6fG:2b4jpZ{BCe3OjeR?= MkXWO|IhcA>? MljvSG1UVw>? MmH3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh\XiycnXzd4lv\yCOS1KxJI12fGGwdDD3bZRpKEeLNUCgc4YhOC5yMEC0N|Uh|ryP MXeyOFkxODJ4Nh?=
A2780 MoD4R5l1d3SxeHnjJGF{e2G7 MmjWO|IhcA>? NHPDO2hFVVOR Mn7nR5l1d3SxeHnjbZR6KGGpYXnud5QhWFSHTj3k[YZq[2mnboSgbJVu[W5iQUK3PFAh[2WubIOge4l1cCCJSUWwJI9nKDBwMECwOlM2KM7:TR?= M4SyWlI1QTByMk[2
U87MG NEnjU5hEgXSxdH;4bYMhSXO|YYm= M1uwdlczKGh? NHXLWYRFVVOR M4fOVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCWRV6t[IVncWOrZX70JIh2dWGwIGW4O21IKGOnbHzzJJdqfGhiR1m1NEBw\iByLkCwNFY6QCEQvF2= NGPpXZUzPDlyMEK2Oi=>
A2780 M1fFT2Z2dmO2aX;uJGF{e2G7 MoXWNUBp M3XPRmROW09? M3jKSWlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6wOVUh|ryP NXHqeYVxOjR7MECyOlY>
DU145 NH7XTVlHfW6ldHnvckBCe3OjeR?= MnjPNUBp MVLEUXNQ MoH3TY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGRWOTR3IHPlcIx{KGijcnLvdolv\yCOS1KxJI12fGG2aX;uJJdqfGhiRVO1NEBw\iByLkC3N{DPxE1? M{TCV|I1QTByMk[2
A2780 MUfGeY5kfGmxbjDBd5NigQ>? M1\4cFEhcA>? NEfyTYFFVVOR NUK5dmVUUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4u\GWoaXPp[Y51KGi3bXHuJGEzPzhyIHPlcIx{KHerdHigSWM2OCCxZjCwMlA4PCEQvF2= MVOyOFkxODJ4Nh?=
MCF7 NFXOeppHfW6ldHnvckBCe3OjeR?= MVexJIg> NVnLN3pzTE2VTx?= NEHJTHdKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDFOVQ2UyCvdYThcpQudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hf2m2aDDFR|UxKG:oIECuNUDPxE1? MUSyOFkxODJ4Nh?=
U87MG NFSzXphHfW6ldHnvckBCe3OjeR?= MXyxJIg> NYnObnFsTE2VTx?= MmL0TY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIlvKFCWRV6t[IVncWOrZX70JIh2dWGwIGW4O21IKGOnbHzzJJdqfGhiRVO1NEBw\iByLkGzJO69VQ>? MmP3NlQ6ODB{Nk[=
A2780 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDOO|IhcA>? NGL1TVVFVVOR M2\mRmVEPTB;MD61NkDPxE1? MYOyOFkxODJ4Nh?=
SKMES-1 MYTDfZRwfG:6aXOgRZN{[Xl? NFexO3UyKM7:TR?= NGm1eHQ4OiCq MkP3TY5lfWOnczDj[YxtKGSnYYTo MlzGNlYxOTN|MUi=
H596 NFTOO4xHfW6ldHnvckBCe3OjeR?= MlH4NUDPxE1? MUfJcZBicXK|IHPlcIwhdWmpcnH0bY9v MW[yOlAyOzNzOB?=
HCC2450 NFjK[3FHfW6ldHnvckBCe3OjeR?= MkO5NUDPxE1? M2H1WGlueGGrcoOgZ4VtdCCrbo\hd4lwdg>? M4PuNFI3ODF|M{G4
A549 MoD1SpVv[3Srb36gRZN{[Xl? M1fiV|UxOCCwTR?= M3vUeVQ5KGh? NVm1R2VGTE2VTx?= Ml;pTY5pcWKrdIOgRYt1KGGldHn2ZZRqd25? MoXoNlU6Ozd{OUm=
A549 M{SzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\yVlEh|ryP MnzYO|IhcA>? NU\GV4J[TE2VTx?= MVzJcohq[mm2czDj[YxtKGe{b4f0bC=> NHPnWoUzPTl|N{K5PS=>
H522 MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVGwNZI1OSEQvF2= NHP6d4c4OiCq MoDrSG1UVw>? MYrJcohq[mm2czDj[YxtKGe{b4f0bC=> M3TUZ|I2QTN5Mkm5
LNCaP NG\IXVRHfW6ldHnvckBCe3OjeR?= MnS1NUDPxE1? NIC3[2RUfXCycnXzd4V{KHBvQVvUJIxmfmWucx?= M3vwS|I2OzZyN{m5
LNCaP95 NEn4OJBHfW6ldHnvckBCe3OjeR?= NIPtWosyKM7:TR?= NHjVe3VUfXCycnXzd4V{KHBvQVvUJIxmfmWucx?= NELEcW0zPTN4MEe5PS=>
HCT-15 Mk\iRZBwfG:|aYOgRZN{[Xl? M3\pWlExKM7:TR?= NYXSXoV5PDhiaB?= MYPEUXNQ MoPpTY5lfWOnczDhdI9xfG:|aYOgbY4hUEOWLUG1JINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? MX2yOVE2OjJ2NR?=
HCT-116 MUTBdI91d3OrczDBd5NigQ>? Mn;qNVAh|ryP NHjJNmQ1QCCq MUTEUXNQ MoTVTY5lfWOnczDhdI9xfG:|aYOgbY4hUEOWLUGxOkBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w NEfPZZMzPTF3MkK0OS=>
NCI-H460 NX7qfXFqSXCxdH;zbZMhSXO|YYm= MWGxNEDPxE1? M3i0bVQ5KGh? MXXEUXNQ NVnsdoNkUW6mdXPld{BieG:ydH;zbZMhcW5iTlPJMWg1PjBiY3XscJMhcGG{Yn;1dolv\yCSSVuzR2EhcG:2c4DveEBufXSjdHnvci=> M13GdlI2OTV{MkS1
SKOV-3 MlnuRZBwfG:|aYOgRZN{[Xl? NFLNZpYyOCEQvF2= MV20PEBp M4PLfGROW09? M1rqd2lv\HWlZYOgZZBweHSxc3nzJIlvKFONT2[tN{Bk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w M4jObVI2OTV{MkS1
BSY-1 MWTBdI91d3OrczDBd5NigQ>? MlzjNVAh|ryP MYi0PEBp MmPaSG1UVw>? MnXITY5lfWOnczDhdI9xfG:|aYOgbY4hSlO\LUGgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>? MXiyOVE2OjJ2NR?=
MKN-1 NUPvd4FxSXCxdH;zbZMhSXO|YYm= MojmNVAh|ryP M{CzOlQ5KGh? NF3iWZhFVVOR NYDNVJpVUW6mdXPld{BieG:ydH;zbZMhcW5iTVvOMVEh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= NVPoSJp{OjVzNUKyOFU>
NCI-H522 MkLIRZBwfG:|aYOgRZN{[Xl? Ml6xNVAh|ryP MVy0PEBp NX3ETFh{TE2VTx?= M1vEcWlv\HWlZYOgZZBweHSxc3nz MYGyOVE2OjJ2NR?=
OVCAR-3 NWTUOZVlSXCxdH;zbZMhSXO|YYm= M1zCblExKM7:TR?= MWC0PEBp NXf4NXBnTE2VTx?= NXOyboRkUW6mdXPld{BieG:ydH;zbZM> NGXZXZozPTF3MkK0OS=>
HBC-5 Mly5RZBwfG:|aYOgRZN{[Xl? MnHCNVAh|ryP MofSOFghcA>? MoTtSG1UVw>? NEWxVWtKdmS3Y3XzJIFxd3C2b4Ppdy=> M1i4d|I2OTV{MkS1
RXF-631L MX7BdI91d3OrczDBd5NigQ>? MXqxNEDPxE1? M3;GZlQ5KGh? MlSzSG1UVw>? MVPJcoR2[2W|IHHwc5B1d3Orcx?= NGG1foYzPTF3MkK0OS=>
MKN-45 M{XEN2Fxd3Sxc3nzJGF{e2G7 NIO1N5MyOCEQvF2= Mm\SOFghcA>? MkWzSG1UVw>? NFLMXnlKdmS3Y3XzJIFxd3C2b4Ppdy=> NVO3[21POjVzNUKyOFU>
BON-1 M3v0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC5bGU2ODBibl2= NHz2RlYyOCCm Mn3ESG1UVw>? NF7BeFRKdmirYnn0d{Bk\WyuIHfyc5d1cA>? Mo\0NlUxOjZ{OUK=
BON-1 NY\0NGdZTnWwY4Tpc44hSXO|YYm= NFvoV4I2ODBibl2= NGK3fHA1KGh? NFLDSGZFVVOR NHPjWYZKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuWIHH0JHRpejNyODDhcoQhW2W{NEez NWHOc3lEOjVyMk[yPVI>
QGP-1 NVvZOVkxTnWwY4Tpc44hSXO|YYm= NXvMdmNpPTByIH7N M4HWWlQhcA>? NVPqWG4{TE2VTx?= NHLQcGFKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuWIHH0JHRpejNyODDhcoQhW2W{NEez NFLiVHczPTB{NkK5Ni=>
Huh7 MYLGeY5kfGmxbjDBd5NigQ>? M4j0[lEh|ryP MYWxJIg> NWPDV4Z1TE2VTx?= MonvTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDT[ZI1PzR? MXWyOVAxPDRyMx?=
BNL NFjSXnBHfW6ldHnvckBCe3OjeR?= NWnqOmxwOSEQvF2= M2fUOlEhcA>? NUizSpRMTE2VTx?= MUTJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gV|Y> MVGyOVAxPDRyMx?=
MDA-MB-175 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e0RVEh|ryP NFXHc|k2KGR? MYHEUXNQ MV3JR|UxRDFizszN M4LiN|I1QDd7N{m2
MDA-MB-134 M2nFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVexJO69VQ>? NGG0eFU2KGR? M{T5OmROW09? NV[3T4t1UUN3MEyxJO69VQ>? M1rSfFI1QDd7N{m2
HCC1500 NX;nPJdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLUUWEyOSEQvF2= NH7NUHc2KGR? M3fETGROW09? M1T2T2lEPTB:MTFOwG0> M1rIOVI1QDd7N{m2
EFM-19 NGnHS29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2xJO69VQ>? MYS1JIQ> NFfjOFBFVVOR MWfJR|UxRDFizszN M1LPcFI1QDd7N{m2
ZR-75-30 NVHyUWRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX2NUDPxE1? NVTTXJBJPSCm MVrEUXNQ NXu1OVVnUUN3MEyxJO69VQ>? NGexfXEzPDh5OUe5Oi=>
MDA-MB-361 NFHhTW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PQSlEh|ryP MWG1JIQ> MlfGSG1UVw>? MnfrTWM2ODxzIN88US=> MkLrNlQ5Pzl5OU[=
T-47D MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrwW4t3OSEQvF2= MX:1JIQ> MVHEUXNQ MYTJR|UxRDFizszN MWWyOFg4QTd7Nh?=
SK-BR-3 Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT2SVIyKM7:TR?= Mk[2OUBl NF3B[GNFVVOR NYriXHFmUUN3MEyxJO69VQ>? MUKyOFg4QTd7Nh?=
UACC-732 NEjtSHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\yNUDPxE1? NG\vW2M2KGR? MmjzSG1UVw>? M4PScWlEPTB:MTFOwG0> NXHwSlROOjR6N{m3PVY>
BT-474 NVu3U|A6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzs[WxKOSEQvF2= M4HNd|Uh\A>? Mom5SG1UVw>? MnXoTWM2ODxzIN88US=> NVvvfVFLOjR6N{m3PVY>
HCC202 M4XVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmq1NUDPxE1? NWnmcoZVPSCm M4fyXmROW09? MWjJR|UxRDFizszN MX2yOFg4QTd7Nh?=
MCF7 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHzcpEyKM7:TR?= NXzJflNWPSCm MWXEUXNQ NVnFcoNSUUN3MEyxJO69VQ>? NFjuUoIzPDh5OUe5Oi=>
MDA-MB-415 NIL4eW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn3dnRSOSEQvF2= NFv4ZWg2KGR? Mo\pSG1UVw>? MofzTWM2ODxzIN88US=> M3TsUlI1QDd7N{m2
MDA-MB-453 MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXIT2NpOSEQvF2= NHnDTYc2KGR? MXTEUXNQ NHfHcYxKSzVyPEGg{txO MkDENlQ5Pzl5OU[=
ZR-75-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:wNXQyKM7:TR?= M2XQUVUh\A>? MlLnSG1UVw>? NXHqeZBVUUN3MEyxJO69VQ>? MkPDNlQ5Pzl5OU[=
HCC38 NEDF[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzvNocyKM7:TR?= NGPFSpA2KGR? M2W5O2ROW09? NYOzU3hqUUN3MEyxJO69VQ>? NGXNUZEzPDh5OUe5Oi=>
HCC1419 M3TTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[xJO69VQ>? NFzlNGc2KGR? M{D4cWROW09? NVWwfHN7UUN3MEyxJO69VQ>? NH60c|MzPDh5OUe5Oi=>
UACC-812 NV\5Z4RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX0NUDPxE1? MW[1JIQ> MYfEUXNQ NGrRfFFKSzVyPEGg{txO NIfnZ4EzPDh5OUe5Oi=>
HCC1187 MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq4V3JYOSEQvF2= MljYOUBl NFPjeXdFVVOR MUTJR|UxRDFizszN Mm\hNlQ5Pzl5OU[=
KPL-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLheFcyKM7:TR?= M1G3SFUh\A>? MoXUSG1UVw>? M{jMOWlEPTB:MTFOwG0> NFXSd4QzPDh5OUe5Oi=>
SUM-225 M1TyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHqc3MyKM7:TR?= MYO1JIQ> M4K1UmROW09? MnPDTWM2ODxzIN88US=> M2juSVI1QDd7N{m2
EFM-192A MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIflfFMyKM7:TR?= NYOyfJh3PSCm M16xZmROW09? Mkn3TWM2ODxzIN88US=> NH7rS3MzPDh5OUe5Oi=>
JIMT-1 NYXHSYJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnvO2tCOSEQvF2= NGC3eoY2KGR? NYrTdWpwTE2VTx?= MXnJR|UxRDFizszN NWPINlRDOjR6N{m3PVY>
HCC1143 MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{noRlEh|ryP MoDsOUBl NH60RmJFVVOR MUXJR|UxRDFizszN NUHndJpLOjR6N{m3PVY>
HCC2218 NYXoVXY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HoblEh|ryP NXXwNJBsPSCm NGriNoxFVVOR MVvJR|UxRDFizszN NFTwXVQzPDh5OUe5Oi=>
MDA-MB-468 NIi0[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjZVlB6OSEQvF2= NUnBZ3VVPSCm M2W3OGROW09? MmW2TWM2ODxzIN88US=> M4nqTFI1QDd7N{m2
BT-20 NEHOfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rGWVEh|ryP MXK1JIQ> NHX2bmVFVVOR M3HReWlEPTB:MTFOwG0> NETMUo8zPDh5OUe5Oi=>
MDA-MB-435 Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXm4O3BzOSEQvF2= NGH1VXQ2KGR? NYSyT3lnTE2VTx?= MVnJR|UxRDFizszN M3K3WlI1QDd7N{m2
BT-549 MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H1NlEh|ryP NXP1eFFwPSCm NXLGOVRCTE2VTx?= NXL3OIVNUUN3MEyxJO69VQ>? NHjlTIozPDh5OUe5Oi=>
HCC1806 MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn2V24yKM7:TR?= M3S0SVUh\A>? MX3EUXNQ NFq3NopKSzVyPEGg{txO NULFNIlZOjR6N{m3PVY>
HCC1937 NHHEO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TuWlEh|ryP M1rwflUh\A>? MkXVSG1UVw>? MmflTWM2ODxzIN88US=> NFzoV4ozPDh5OUe5Oi=>
Hs578T NF\wR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSxJO69VQ>? NYrmeFdYPSCm MWfEUXNQ MVLJR|UxRDFizszN M3fkOlI1QDd7N{m2
LN18 NH;XVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPF[4MzOCEQvF2= MUi3NkBp NEPzcmpFVVOR NIPMRmRKSzVyPEWg{txO MonhNlQ4PDFyN{S=
LN229 NHPmS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVmyNEDPxE1? MmDBO|IhcA>? NYDLcJdCTE2VTx?= NWDH[YFDUUN3MEy1JO69VQ>? NInjWHkzPDd2MUC3OC=>
LNZ308 M17DdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPkNlAh|ryP M2HYbVczKGh? MXfEUXNQ MV\JR|UxRDVizszN MWSyOFc1OTB5NB?=
T98G M332W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnQUpgzOCEQvF2= NVewdFFwPzJiaB?= NXz1PJJxTE2VTx?= MUHJR|UxRDVizszN MXyyOFc1OTB5NB?=
U87 Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzveJMzOCEQvF2= NH[4Ooo4OiCq NXSzR2VJTE2VTx?= NUfJTWVsUUN3MEy1JO69VQ>? Mor3NlQ4PDFyN{S=
LN18 NX7OWo8yTnWwY4Tpc44hSXO|YYm= NIrxXFY2KM7:TR?= MU[yOEBp MV7EUXNQ MoL0TY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? M{\0VFI1PzRzMEe0
LNZ308 MX7GeY5kfGmxbjDBd5NigQ>? NGD0OWU2KM7:TR?= NE\oeVAzPCCq M3vxN2ROW09? MlrNTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? MVyyOFc1OTB5NB?=
Saos-2 NED1dYJHfW6ldHnvckBCe3OjeR?= NXHxb41vPTBizszN NYjlPJhYPDhiaB?= M2TuOGlvcGmkaYTzJINmdGxiaX72ZZNqd25? M36wVlI1PzJ5Nk[w
MG-63 MUXGeY5kfGmxbjDBd5NigQ>? MmfUOVAh|ryP NUDuNYVLPDhiaB?= NHu2XpBKdmirYnn0d{Bk\WyuIHnueoF{cW:w MViyOFczPzZ4MB?=
SJSA-1 NVnEN3RJTnWwY4Tpc44hSXO|YYm= NGHSemM2OCEQvF2= MV:0PEBp M4fKfGlvcGmkaYTzJINmdGxiaX72ZZNqd25? MV:yOFczPzZ4MB?=
Saos-2 MmezSpVv[3Srb36gRZN{[Xl? M3vhdVUxKM7:TR?= MUG0PEBp M2LKb2lvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> M3;od|I1PzJ5Nk[w
MG-63 NGLob3hHfW6ldHnvckBCe3OjeR?= MXu1NEDPxE1? M4\2XFQ5KGh? NXPkNnp2UW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? NYrpS2VFOjR5Mke2OlA>
SJSA-1 MmLMSpVv[3Srb36gRZN{[Xl? MXK1NEDPxE1? NFvHVm41QCCq M1\vOWlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> NY[1SGFkOjR5Mke2OlA>
Saos-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3uycVUxKM7:TR?= MnH2OFghcA>? Mn24TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MViyOFczPzZ4MB?=
MG-63 M33VTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[yV|UxKM7:TR?= M4DCb|Q5KGh? Mn7QTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? M{XkW|I1PzJ5Nk[w
SJSA-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2iwZVUxKM7:TR?= NWqySplzPDhiaB?= MnrxTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MlfmNlQ4Ojd4NkC=
FaDu NFfJOVdHfW6ldHnvckBCe3OjeR?= MnLQOUDPxE1? M3jUN|I1KGh? NXL5e3VSTE2VTx?= NGXNS4tT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> NHnJRYMzPDZ|MUG0Oy=>
EMT6 NITxNFNHfW6ldHnvckBCe3OjeR?= NHr0WHM2KM7:TR?= NESwNY0zPCCq MVnEUXNQ NX;QbmhFWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> NGLSeFczPDZ|MUG0Oy=>
HCT116 NVLrVYpLTnWwY4Tpc44hSXO|YYm= MonDOUDPxE1? MYKyOEBp NGXYbW9FVVOR NFvKOmlT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> M3TDR|I1PjNzMUS3
U87 NFTONVBHfW6ldHnvckBCe3OjeR?= M3XRRlUh|ryP M1nUOlI1KGh? NHXtbXNFVVOR MXjS[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= MVSyOFY{OTF2Nx?=
GBM NIfOOnZCeG:ydH;zbZMhSXO|YYm= M4jFdFLPxE1? NHixSYU1QGh? Ml7USG1UVw>? MnXSbY5lfWOnZDDobYdp\XJibHX2[Yx{KG:oIHHwc5B1d3OrczygZY5lKGSnY4LlZZNm\CClZXzsJJZq[WKrbHn0fS=> MVyyOFUxODR7Mh?=
BON MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LYPFEuPc7:TR?= MV23Nog> NYDH[Xdu\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>? MYSyOFQ1OzV{Mx?=
BON MoeyRZBweHSxc3nzJGF{e2G7 MoXINU02|ryP MUKyOIg> NIDIWXFqdmO{ZXHz[ZMh[XCxcITvd4l{ NEHTcnMzPDR2M{WyNy=>
H1975 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrwNZc1OC5|LUmuOu69VQ>? MoTlO|Jp MkXFSG1UVw>? M3\td2lEPTB;MT6zPFXPxE1? NV7Zc2hvOjR|M{e4OFY>
H1975 MWTBdI9xfG:|aYOgRZN{[Xl? MW[y{txO MmXKNlRp NVn5epdqTE2VTx?= MoHRbY5kemWjc3XzJIFxd3C2b4Ppd{Bz[XSnIIPp[45q\mmlYX70cJk> M1zoZ|I1OzN5OES2
T-ALL NVnYNIw3SXCxcITvd4l{KEG|c3H5 NWm1[IlD[mW2d3XlckAyNjRiYX7kJFUvOyCvTTDheEAzPGhiYX7kJFAvQSCjbnSgOU42KG2PIHH0JFQ5cCCrbjDkbYZn\XKnboSgZ4VtdCCuaX7l NY\0U25XOjRib4KgOFhp NXKyUWQ4TE2VTx?= Mkj2ZYZn\WO2czD0bIUhWEl|SzDwZZRpf2G7IHnuJHQuSUyOIHPlcIwhdGmwZYO= NGrQcW8zPDNzMEezOi=>
BCR-ABL M2POcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX65TFNOOC5{NT2xNO69VQ>? MkS2OIQ> Ml;Ud4lodmmoaXPhcpRtgSCrbnjpZol1KGOnbHygdJJwdGmoZYLheIlwdg>? NWXhTHJ4OjR{NES2NVI>
LC-1/SQSF M4KwUWZ2dmO2aX;uJGF{e2G7 Mm\3N:69VQ>? M1:0SlI1cA>? M1\HdWROW09? M1e2WoRm[3KnYYPlJG5TTjJicILveIVqdiCuZY\lcC=> NGG0W|UzOzl6MEC5Ny=>
Primary CLL cells Mn7wRZBweHSxc3nzJGF{e2G7 NGTLdFcyNTFyzszN Ml:zOFhp NF22XpFqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCFTFygZ4VtdHNiaX7k[ZBmdmSnboSgc4YheHKxZ37vd5Rq[yCvYYLr[ZJ{ NEHxdoEzOzh3MEiwOy=>
Primary CLL cells Mm\4T4lv[XOnIFHzd4F6 NF;EUFEz|ryP NWTuT5pzOzCvaX6= MmSy[IVkemWjc3XkJHBKO0tiYXP0bZZqfHl? Mmf2NlM5PTB6MEe=
Primary CLL cells NEXtXGlEgXSxdH;4bYMhSXO|YYm= MnfMNu69VQ>? NXPie3VMOjSq NEjoTYNqdmS3Y3XzJINmdGxiY4n0c5RwgGmlaYT5 NYjHfZhDOjN6NUC4NFc>
human NSCLC cell lines MmnsRZBweHSxc3nzJGF{e2G7 Mo\tNE4yOjVvNN88US=> MkLHNlRp MljISG1UVw>? NFjW[llKSzVyczDyZY5o\XNiZoLvcUAxNjRvMt88US=> MWSyN|U3OjR5Mh?=
human HCC cell lines MmrsR4VtdCC4aXHibYxqfHliYYPzZZk> M1r1UVAvODB3LUJOwG0> NGj5elI1QGh? MXzJR|UxRTIQvF2= M1PpdVI{PDh7OUm5
Huh7 NIXnNWhMcW6jc3WgRZN{[Xl? MmPHNe69VQ>? M4[2ZVQ5cA>? NGe0TVZ{cWewaf-shYNidnSueTDy[YR2[2W|IIDoc5NxcG:{eXzheIlwdiCxZjDBb5Q> M4nWUFI{PDh7OUm5
SK-HEP1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVqzU2IxOS1{MN88US=> NEjkS4g4Omh? NIniS21FVVOR M3;xVWlEPTExvKyx{txO M2K4RlI{PDd7MUO2
786-0 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLRNU0zOM7:TR?= MmrGO|Jp MnX3SG1UVw>? M3u5R2lEPTExvKyx{txO MlvWNlM1PzlzM{[=
JVM2 MWjDfZRwfG:6aXPpeJkh[XO|YYm= M{PSfFAvOi1{MN88US=> MmLVO|Jp NVHWOZNiTE2VTx?= MmnKTWM2OD1yLkpOwG0> M2S1b|I{OjN6NkO5
EHEB NInFO5dEgXSxdH;4bYNqfHliYYPzZZk> M2rJN|AvOi1{MN88US=> MXO3Nog> NGq1R|FFVVOR M1\NZWlEPTB;MD63{txO NVzlZlhKOjN{M{i2N|k>
MEC2 NX\LTopOS3m2b4TvfIlkcXS7IHHzd4F6 NX3CZ3MxOC5{LUKw{txO MnjtO|Jp Mn3VSG1UVw>? NXzGb49HUUN3ME2wMlfPxE1? M4q0eVI{OjN6NkO5
primary B-CLL lymphocytes NGrvcWhCeG:ydH;zbZMhSXO|YYm= M3nrbGlEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV? NYryVWllOjSq NEfZWnRFVVOR NHjqUnRKSzVy78{cN:69VSCob4KgZYxtKHCjdHnlcpR{ NGHvdHYzOzJ|OE[zPS=>
primary B-CLL lymphocytes M4rsRmtqdmG|ZTDBd5NigQ>? M3rpc2lEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV? MYCyOIg> M3fBS4lvcGmkaYTzJJA4OFN4SzCmJFRGNUKSMTDlfJBz\XO|aX;u MorBNlMzOzh4M{m=
human NSCLC MljZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXOwMlUuOs7:TR?= M4nn[lczcA>? NWjVfHNLUUN3ME2x{txO M2\oOVIzPzhzM{mz
human NSCLC Mn[xT4lv[XOnIFHzd4F6 NV7xbFdvOc7:TR?= MnmyNlRp NH3IbWVqdmirYnn0d{B1cGViQXv0M41VV1Jic3nncoFtcW6pIIDheIh4[XliYYSgN4gh[W[2ZYKgeJJm[XSvZX70 MkDhNlI4QDF|OUO=
Y1 cell line MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDCV20xNjIQvF2vNe69VQ>? NEi3UFczPGh? Mo[4SG1UVw>? NUjoeXl6cW6qaXLpeJMhPjExvJWgZ4VtdCC4aXHibYxqfHliaX6gUZlkNVOldIKteJJidnOoZXP0[YQh[2WubIO= NID2Vo4zOjZ7MkmwOC=>
PIK3CA-mutant MCF7 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j1ZWdKPTB;MU[wxtE6OW6P78{MUGQ2OD17OEFCtVI4O26P NVe0ellUPzKq M1zBZ2dKPTB;MU[wxtE6OW6P78{MUGQ2OD17OEFCtVI4O26P M1HwPVIzPjV|OU[3
PIK3CA-mutant MCF7 MnLET4lv[XOnIFHzd4F6 NGXKPI1KSzVyPUGxOOKyO26P MV63Nog> MYrJR|UxRTFzNNMxN45OKGmwIILl[JVkcW6pIFHreEBxcG:|cHjvdplt[XSrb36gcIV3\Wy| NFmyU2szOjZ3M{m2Oy=>
MCF7-myr-Akt MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL2b|NoT0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2= NF[zNlk4Omh? MXzHTVUxRTJ7OdMxOlhvVe,:jFzEOVDwxJ5zMDywNFBvVQ>? Mn3GNlI3PTN7Nke=
colon cancer cell lines M4TSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYm0c5pDOC1zMN88US=> MnvtO|Jp NFfzfGdFVVOR MlnsTWM2OD1zzszN NV\O[pp5OjJ3NEO4OVc>
gastric cancer cell lines NUnVdJQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e1V|AuOTEQvF2= NXjZUVRPPzKq NWT3N5cxTE2VTx?= NVHtR2lPUUN3ME2yMVXPxE1? MnXONlI2PDN6NUe=
HCT-116/HT-29/MKN-45 M2i4[WFxd3C2b4Ppd{BCe3OjeR?= NFXBTWcz|ryP NF;6WmQ1QGh? MX3zbIlnfCCrbjDHNkBxcGG|ZR?= MmXSNlI2PDN6NUe=
HT-29 and HCT-116 NXLrb2kyS2G|cHHz[UBie3OjeR?= MVW1{txO M2LKelI1cA>? M{SxUYlv\HWlZYOgZ4F{eGG|ZTDhZ5Rqfmm2eR?= Mn7lNlI2PDN6NUe=
MM cell lines MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXKNVDPxE1? NXrlPWJVOjSq NXnR[IxLTE2VTx?= MofNTWM2OCC4YYLp[ZMh[W2xbneg[Iln\mW{ZX70JINmdGxibHnu[ZMhcW5idHnt[UBidmRiZH;z[UBl\XCnbnTlcoNm NH\pWpczOjJyN{S4OS=>
ARP-1 Mn7wRZBweHSxc3nzJGF{e2G7 M2rOUVEx|ryP NFHuXo4zPGh? MUfEUXNQ M{niWYlv\HWlZYOgUW0h[2WubDDhdI9xfG:|aYOgeIhzd3WpaDDjZZNx[XOnIHHjeIl3[XSrb36= MmrTNlIzODd2OEW=
SNU-601 NUPwPJZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL5fpk4Omh? NYP0cGdsTE2VTx?= M3n2UmlEPTB;MD64NVbDuTBwME[z{txO NIj5N2kzOjF3OUixOC=>
SNU-1 NGK0R|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;6ZlczcA>? M{fjNGROW09? NF7ERWxKSzVyPUGuNFgzyrFyLkCyPO69VQ>? NXi4Uo15OjJzNUm4NVQ>
SNU-668 M3Hncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUi3Nog> MWrEUXNQ NYDHV|FkUUN3ME2xMlU4QcLzMD6wO|TPxE1? NW\DeY5JOjJzNUm4NVQ>
AGS MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHJcHA4Omh? MkHqSG1UVw>? NHzI[IZKSzVyPUGuO|E1yrFyLkGxO:69VQ>? NH3PcVEzOjF3OUixOC=>
SNU-216 NF;OcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\nSlczcA>? NHjpd2JFVVOR MX\JR|UxRTJwNkmyxtExNjB6Mt88US=> M1\xNFIzOTV7OEG0
SNU-5 M2n5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDnO|Jp NFLyZWRFVVOR MWTJR|UxRTFwM{WxxtExNjB7Md88US=> MVOyNlE2QThzNB?=
SNU-638 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fYfFczcA>? NXvvRZR{TE2VTx?= Mln3TWM2OD1{LkK4NuKyOC5yNUROwG0> NEjGSnczOjF3OUixOC=>
SNU-16 NILFfplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnZWZQyPzKq MVXEUXNQ NWfH[moxUUN3ME2xMlU4O8LzMD6wNFHPxE1? NWfTSnZuOjJzNUm4NVQ>
SNU-484 M2Lqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT5W|Y6PzKq NGX6Z|ZFVVOR MX;JR|UxRTFwN{K4xtExNjB2Nd88US=> NEnEbG8zOjF3OUixOC=>
SNU-620 MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv0O|Jp NHvWOYdFVVOR NU\1OVVSUUN3ME2yMlk{QcLzMD6wNFHPxE1? NUTsPGFEOjJzNUm4NVQ>
SNU-719 NFjh[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nU[VczcA>? M1HFSWROW09? NYi4XJd{UUN3ME2zMlA{P8LzMD6wN|LPxE1? MViyNlE2QThzNB?=
glioma cell lines MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3mzelczcA>? MVfJR|UxRTFvMt88US=> MV2yNlA3PTB6MB?=
U87 MUjBdI9xfG:|aYOgRZN{[Xl? MXey{txO Mo\XO|Jp MV\pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGGwZDDjcIVifmWmIGDBVnAh[W6mIHPhd5Bie2VvMx?= Mlv6NlIxPjVyOEC=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-AKT (T308) / p-AKT (S473) / AKT; 

PubMed: 27283525     


Left western blots showing levels of pAkt (T308), pAkt (S473) and total Akt in U87 cells exposed to buparlisib for 72 h. Right densitometric assessment of western blots, showing relative changes in phosphorylation.

p-FOXO3a (S253) / FOXO3a; 

PubMed: 28036259     


Cells were treated with 0.5 μM BKM120 for 24 h and cell lysates were immunoblotted with the indicated antibodies. Actin was used as the loading control.

Nuclear NF-κB p65 / NF-κB p65; 

PubMed: 26673665     


Western blots show BKM120 downregulating pAKT, nuclear NF-κB p65 and total NF-κB p65 in MDR and their parental cells. β-actin was used as a loading control for pAKT, AKT and total NF-κB p65. Lamin B was used as a loading control for nuclear NF-κB p65. 

p-ERK / ERK / LC3; 

PubMed: 27572309     


The indicated cell lines were exposed to different concentrations of BKM120 as indicated for 8 h A. or with 2 μM BKM120 for the indicated times B. The cells were then harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis to detect the given proteins.

p-STAT3 / STAT3 / p-ERK / ERK / p-S6; 

PubMed: 29928341     


Western blot analysis of H460 and H2126 cell lysates using specific antibodies to phosphorylated or total proteins of STAT3, ERK1/2, AKT, S6 or GAPDH (loading control). The cells were treated with increasing concentrations of BKM120 for 24 h.

p-MET / MET; 

PubMed: 29928341     


The expression of phosphorylated or total forms of MET protein was analyzed by western blotting. 

27283525 28036259 26673665 27572309 29928341
Immunofluorescence
FOXO3a; 

PubMed: 28036259     


Cells were cultured on coverslips to approximately 60% confluency and then treated with 1 μM BKM120 for an additional 24 h. Immunofluorescence staining was performed using an anti-FOXO3a antibody and the nuclei were stained with DAPI. Scale bar, 20 μm.

28036259
Growth inhibition assay
Cell viability; 

PubMed: 26673665     


Dose-response curves were used to calculate the IC50 of BKM120 for MCs of MCF-7/A02 cells (upper) and CALDOX cells (lower).

26673665
体内研究 BKM120按30, 60, 或100 mg/kg剂量作用于A2780移植瘤，完全抑制pAKTser473。BKM120按 30和 60 mg/kg剂量作用于U87MG神经胶质瘤模型，显示抗癌活性。[1]BKM120每天按5μM/kg剂量处理具有持久生命力的ARP1 SCID鼠模型，导致肿瘤体积和K链水平明显降低。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[2]
+ 展开

PI3K 生化实验(ATP 消耗实验):

BKM120溶于DMSO中，按每孔1.25 µL直接加到黑色384孔板上。开始反应, 25 µL 10nM PI3K和5 µg/mL 1-α-磷酸肌醇(PI)加到实验 buffer (10 mM Tris pH 为7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT，及0.05% CHAPS)，然后加到每孔中，随后在实验buffer中加入25 µL 2 µM ATP。反应进行直到50% ATP被消耗，然后加入25 µL KinaseGlo溶液终止反应。终止的反应温育5分钟，然后通过荧光测定残留的ATP。
细胞实验：[1]
+ 展开
  • Cell lines: A2780细 胞
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3天
  • Method: A2780细胞培养在含10% FBS,L-谷氨酸,丙酮酸钠和抗生素的DMEM培养基上。细胞按每孔103个细胞的密度接种在相同培养基上，温育3到5小时。稀释溶于20 mM DMSO中的BKM120。2 µL稀释的BKM120溶液加到细胞培养基上, (浓度为0-6.6 µM)。等体积(100 µL)溶液加到96孔板中，在37oC下温育3天。使用Trilux读取荧光值而测定抑制细胞增殖的效果
    (Only for Reference)
动物实验：[1]
+ 展开
  • Animal Models: 携带U87MG 和A2780移植瘤的雌性裸鼠
  • Formulation: 15% Captisol
  • Dosages: ~60 mg/kg
  • Administration: 每天口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
5% DMSO+30% PEG 300+ddH2O
 15mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 410.39
化学式

C18H21F3N6O2
CAS号 944396-07-0
储存条件 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02614508 Terminated Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2
NCT01953445 Withdrawn Breast Neoplasms Washington University School of Medicine August 2014 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项
Selleck产品目录册

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

  • Taselisib (GDC 0032) New

    Taselisib (GDC 0032)是一种有效，下一代的β亚型PI3K抑制剂，作用于PI3Kα/δ/γ， IC50分别为0.29 nM/0.12 nM/0.97nM，比作用于PI3Kβ选择性高10倍以上。

  • Pilaralisib (XL147) New

    Pilaralisib (XL147)是一种选择性的可逆I型PI3K抑制剂，作用于PI3Kα/δ/γ，在无细胞试验中IC50为 39 nM/36 nM/23 nM，对PI3Kβ作用较低。Phase 1/2。

  • GNE-317 New

    GNE-317 是一种有效的，大脑渗透性 PI3K 抑制剂。

  • LY294002

    LY294002 是首个合成的已知抑制PI3Kα/δ/β的小分子，在无细胞测定中IC50分别为 0.5 μM/0.57 μM/0.97 μM；在溶液中比在Wortmannin中稳定，也能够阻断自噬体的形成。它不仅能够结合class I PI3Ks和其他PI3K相关的激酶，还能够结合一些与PI3K家族无关的新型靶点。

    Features:LY294002是选择性的, 可渗透细胞的特定PI3K抑制剂，可作用于酶的ATP结合位点，且抑制自体吞噬的螯合作用。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA)是一种选择性PI3K抑制剂，作用于Vps34和PI3Kγ，在 HeLa细胞中IC50分别为25 μM和60 μM；永久性抑制I型PI3K，但对III型PI3K的抑制是短暂的，也会阻断自噬体的形成。现配现用（加热助溶）。

  • Idelalisib (CAL-101, GS-1101)

    Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂，在无细胞试验中IC50为 2.5 nM；对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍，对p110δ的选择性是对 C2β，hVPS34，DNA-PK 和 mTOR的400到4000倍。

    Features:Calistoga 暗示 CAL-101治疗血液恶性肿瘤可能有更广泛的应用价值。

  • Wortmannin

    Wortmannin是一种首次命名的PI3K抑制剂，在无细胞试验中IC50为3 nM，对 PI3K 家族的选择性较低。也会抑制自噬体的形成，并有效抑制DNA-PK/ATM，在无细胞试验中IC50为16 nM和150 nM。

  • Dactolisib (BEZ235, NVP-BEZ235)

    Dactolisib (BEZ235, NVP-BEZ235) 是一种双重ATP竞争性 PI3K 和 mTOR 抑制剂，在无细胞试验中，抑制 p110α/γ/δ/β 和 mTOR(p70S6K) 的 IC50 分别为 4 nM /5 nM /7 nM /75 nM /6 nM。 在 3T3TopBP1-ER 细胞中抑制 ATR，IC50 为 21 nM，而对 Akt 和 PDK1 的抑制作用很弱。Phase 2。

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941) 是一种有效的PI3Kα/δ抑制剂，在无细胞试验中IC50为 3 nM，对p110β (11倍)和p110γ (25倍)具有适度的选择性。Phase 2。

  • Alpelisib (BYL719)

    Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂，在无细胞试验中IC50为 5 nM，对PI3Kβ/γ/δ具有极弱的作用。Phase 2。

Tags: 购买Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)供应商 | 采购Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)价格 | Buparlisib (BKM120, NVP-BKM120)生产 | 订购Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID